Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18870816 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL207772 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL1230711 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL5697575 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL2583898 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL16805415 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL547089 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL4286246 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21423108 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL30694436 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | claimed |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2006-06-08 | — | — | US | claimed |
| EP-1581547-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004050678-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2004-06-17 | — | — | WO | claimed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | disclosed |
| WO-2010037134-A2 | MULTI-STAGE STEM CELL CARCINOGENESIS | STEMLIFELINE, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | disclosed |
| EP-1812456-A2 | ß-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2006-06-08 | — | — | US | disclosed |
| WO-2006045616-A2 | β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-05-04 | — | — | WO | disclosed |
| EP-1581547-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004050678-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0068268-A1 | Enhancer of anti-tumour effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | LMNA 2752/4885MTOR 664/4885ALDH1A1 441/4885 |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | LMNA 2472/4885MTOR 4190/4885ALDH1A1 3050/4885 |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | LMNA 2752/4885MTOR 664/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.